Mercer Global Advisors Inc. ADV purchased a new stake in shares of Novartis AG (NYSE:NVS) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 43,253 shares of the company’s stock, valued at approximately $3,712,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Truvestments Capital LLC bought a new position in shares of Novartis during the 1st quarter worth about $25,000. Canton Hathaway LLC bought a new position in shares of Novartis during the 1st quarter worth about $26,000. AlphaMark Advisors LLC bought a new position in Novartis in the 4th quarter valued at about $30,000. Laurel Wealth Advisors LLC bought a new position in Novartis in the 4th quarter valued at about $35,000. Finally, Executive Wealth Management LLC bought a new position in Novartis in the 4th quarter valued at about $36,000. 11.69% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages recently weighed in on NVS. Zacks Investment Research cut shares of Novartis from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 11th. Morgan Stanley lowered shares of Novartis from an “equal weight” rating to an “underweight” rating and increased their price objective for the company from $82.50 to $82.52 in a research note on Wednesday, April 10th. Guggenheim upgraded shares of Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price objective for the company in a research note on Wednesday, April 24th. Liberum Capital upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Finally, JPMorgan Chase & Co. restated a “sell” rating on shares of Novartis in a research note on Tuesday, January 29th. Five analysts have rated the stock with a sell rating, four have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Novartis presently has an average rating of “Hold” and an average target price of $87.57.
Novartis (NYSE:NVS) last issued its earnings results on Wednesday, April 24th. The company reported $1.21 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.10. Novartis had a net margin of 24.55% and a return on equity of 16.75%. The company had revenue of $11.11 billion for the quarter, compared to analysts’ expectations of $11.76 billion. During the same quarter last year, the company earned $1.28 EPS. The firm’s revenue was up 1.7% compared to the same quarter last year. As a group, equities analysts forecast that Novartis AG will post 4.95 earnings per share for the current fiscal year.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Further Reading: Backdoor Roth IRA Conversion and Strategy
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.